RLI Corp. (RLI) At $64.74 Forms Top; Veru (VERU) Shorts Up By 23.22%

RLI Corp. (NYSE:RLI) Logo

Veru Inc (NASDAQ:VERU) had an increase of 23.22% in short interest. VERU’s SI was 316,300 shares in May as released by FINRA. Its up 23.22% from 256,700 shares previously. With 292,400 avg volume, 1 days are for Veru Inc (NASDAQ:VERU)’s short sellers to cover VERU’s short positions. The SI to Veru Inc’s float is 1.12%. The stock increased 1.06% or $0.02 during the last trading session, reaching $1.9. About 90,933 shares traded. Veru Inc. (NASDAQ:VERU) has risen 64.49% since May 5, 2017 and is uptrending. It has outperformed by 52.94% the S&P500.

RLI Corp. (RLI) formed multiple top with $68.62 target or 6.00% above today’s $64.74 share price. RLI Corp. (RLI) has $2.87 billion valuation. The stock increased 2.53% or $1.6 during the last trading session, reaching $64.74. About 275,008 shares traded or 93.08% up from the average. RLI Corp. (NYSE:RLI) has risen 8.68% since May 5, 2017 and is uptrending. It has underperformed by 2.87% the S&P500.

Investors sentiment increased to 1.57 in 2017 Q4. Its up 0.21, from 1.36 in 2017Q3. It improved, as 7 investors sold RLI Corp. shares while 49 reduced holdings. 27 funds opened positions while 61 raised stakes. 37.42 million shares or 3.33% more from 36.22 million shares in 2017Q3 were reported. Morgan Stanley holds 0% or 207,098 shares in its portfolio. Bluecrest Cap Mngmt Ltd reported 11,355 shares. Eulav Asset Mgmt holds 151,700 shares or 0.43% of its portfolio. Principal Fincl Group Inc Inc has invested 0.02% of its portfolio in RLI Corp. (NYSE:RLI). Riverhead Capital Mgmt Lc holds 3,484 shares or 0.01% of its portfolio. Segall Bryant & Hamill Lc has 5,200 shares for 0.01% of their portfolio. 2,464 are held by National Bank Of Montreal Can. Raymond James Ser Incorporated reported 10,195 shares stake. Assetmark owns 26 shares. Vaughan David Invests Inc Il stated it has 1.48% of its portfolio in RLI Corp. (NYSE:RLI). Moreover, Thrivent Fin For Lutherans has 0% invested in RLI Corp. (NYSE:RLI) for 24,136 shares. The Pennsylvania-based Vanguard Grp Inc has invested 0.01% in RLI Corp. (NYSE:RLI). Van Berkom And Associate Inc reported 875,960 shares. 36 are owned by Parkside Bank & Trust. Bokf Na reported 6,661 shares.

Since January 4, 2018, it had 1 insider purchase, and 6 selling transactions for $635,403 activity. On Thursday, January 4 STONE MICHAEL J sold $67,778 worth of RLI Corp. (NYSE:RLI) or 1,141 shares. Another trade for 900 shares valued at $58,291 was made by Diefenthaler Aaron Paul on Monday, January 29. RESTREPO ROBERT P JR bought $43,490 worth of stock or 675 shares. The insider AHLMANN KAJ sold $99,617.

Among 6 analysts covering RLI Corporation (NYSE:RLI), 0 have Buy rating, 3 Sell and 3 Hold. Therefore 0 are positive. RLI Corporation has $58.0 highest and $40 lowest target. $50.17’s average target is -22.51% below currents $64.74 stock price. RLI Corporation had 25 analyst reports since July 22, 2015 according to SRatingsIntel. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Monday, December 4 report. The rating was maintained by RBC Capital Markets on Wednesday, October 21 with “Sector Perform”. FBR Capital maintained RLI Corp. (NYSE:RLI) on Thursday, July 20 with “Hold” rating. As per Wednesday, October 18, the company rating was maintained by Keefe Bruyette & Woods. The stock has “Sell” rating by RBC Capital Markets on Friday, October 20. RBC Capital Markets maintained RLI Corp. (NYSE:RLI) rating on Thursday, April 19. RBC Capital Markets has “Sell” rating and $5600 target. The company was maintained on Monday, June 26 by RBC Capital Markets. RBC Capital Markets maintained it with “Sell” rating and $5000 target in Monday, July 31 report. The rating was downgraded by RBC Capital Markets on Friday, December 9 to “Underperform”. The stock has “Hold” rating by Keefe Bruyette & Woods on Thursday, August 17.

Another recent and important Veru Inc. (NASDAQ:VERU) news was published by Nasdaq.com which published an article titled: “Veru to Report Fiscal 2018 Second-Quarter Financial Results, Host Conference Call on May 9th” on May 03, 2018.

Veru Inc., a medical therapeutics company, develops, makes, and markets consumer health care products. The company has market cap of $101.68 million. The companyÂ’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever. It currently has negative earnings. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus.

RLI Corp. (NYSE:RLI) Institutional Positions Chart